Recombinant ERG antibody

Catalog No. ABIN7880734

The Mouse Monoclonal anti-ERG antibody (Clone rERG-6843) (ABIN7880734) specifically detects ERG in IHC (p). The antibody is reactive with Human samples.

Quick Overview for Recombinant ERG antibody (ABIN7880734)

Target: ERG (ERG, ETS transcription factor (ERG))

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This ERG antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Grade: Carrier-free

Clone: RERG-6843

Product Details anti-ERG Antibody

Purpose: Transcriptional regulator ERG Antibody / ERG (azide and preservative free)

Purification: Protein A/G affinity

Immunogen: A portion of amino acids 450 to 479 was used as the immunogen for the Transcriptional regulator ERG antibody.

Isotype: IgG1, kappa

Application Details

Application Notes: Optimal dilution of the Transcriptional regulator ERG antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: -20 °C

Storage Comment: Aliquot the Transcriptional regulator ERG antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for ERG

Target: ERG (ERG, ETS transcription factor (ERG))

Alternative Name: Transcriptional regulator ERG

Background: ERG (ETS-related gene) is a proto-oncogene, a member of the ETS family of transcription factors. The ERG gene encodes for a nuclear protein, also called ERG, which is involved in hematopoietic and endothelial development. ERG remains constitually expressed in endothelial cells in blood and lymphatic vessels, and in bone marrow stem cells. ERG is expressed in virtually all endothelial neoplasms including hemangioendothelioma, angiosarcoma and Kaposi sarcoma. ERG is overexpressed secondary to gene rearrangement in cases of prostate adenocarcinoma, gastrointestinal stromal tumor, synovial sarcoma, meningioma, epithelioid sarcoma, malignant rhabdoid tumor, acute myeloid leukemia and blastic extramedullary myeloid tumor, and rarely Ewing sarcoma / primitive peripheral neuroectodermal tumor, chondrosarcoma, osteosarcoma, and rhabdomyosarcoma. For the identification of endothelial differentiation ERG seems more sensitive and specific than any other marker. Moreover, the interpretation is often easier due to the nuclear reaction, which also allows for double stains with cytoplasmic markers like podoplanin. Among carcinomas, ERG is highly specific for prostate, while the sensitivity is moderate.

UniProt: P11308